The dose of 50 mg/kg of methyleugenol was used because of its good performance in behavioral tests. The experimental groups received dexamethasone (64 μg/kg s.c.) about 3 h 30 min before the beginning of the evaluation; we chose the tail suspension test for this step.
To ascertain the participation of the noradrenergic system in the antidepressant activity of methyleugenol, Prazosin, an α1 receptor antagonist [53 (link),55 (link)], was used. Afterward, the different groups received the following treatments: vehicle (Tween 80 1% i.p.), ME (50 mg/kg i.p.), or prazosin (1 mg/kg i.p.). The other group received ME administration 15 min after the prazosin application. After 45 min, we performed the tail suspension test.
To investigate the serotoninergic pathway, p-chlorophenylalanine (PCPA 100 mg/kg i.p.), an inhibitor of tryptophan hydroxylase-serotonin synthesis [55 (link)], was used. We also organized two other groups that received the administration of PCPA daily for 5 days; thus, on the day of the experiment, 30 min prior to the test, one group received the methyleugenol (50 mg/kg i.p.) and the other group the saline. After 30 min, we submitted the animals to the tail suspension test.
We used SCH23390 (a D1 receptor antagonist) to investigate the dopaminergic system [35 (link)]. The groups used received vehicle (Tween 80 1% i.p.), methyleugenol (50 mg/kg i.p.), or SCH23390 (1 mg/kg s.c.). Another group received SCH23390, and after 15 min, received methyleugenol. After 30 min, we started the tail suspension test.
To ascertain the participation of the noradrenergic system in the antidepressant activity of methyleugenol, Prazosin, an α1 receptor antagonist [53 (link),55 (link)], was used. Afterward, the different groups received the following treatments: vehicle (Tween 80 1% i.p.), ME (50 mg/kg i.p.), or prazosin (1 mg/kg i.p.). The other group received ME administration 15 min after the prazosin application. After 45 min, we performed the tail suspension test.
To investigate the serotoninergic pathway, p-chlorophenylalanine (PCPA 100 mg/kg i.p.), an inhibitor of tryptophan hydroxylase-serotonin synthesis [55 (link)], was used. We also organized two other groups that received the administration of PCPA daily for 5 days; thus, on the day of the experiment, 30 min prior to the test, one group received the methyleugenol (50 mg/kg i.p.) and the other group the saline. After 30 min, we submitted the animals to the tail suspension test.
We used SCH23390 (a D1 receptor antagonist) to investigate the dopaminergic system [35 (link)]. The groups used received vehicle (Tween 80 1% i.p.), methyleugenol (50 mg/kg i.p.), or SCH23390 (1 mg/kg s.c.). Another group received SCH23390, and after 15 min, received methyleugenol. After 30 min, we started the tail suspension test.
Free full text: Click here
